Clinical Trial Investigates Orbsen Therapeutics’ ORBCEL-C™ Immunotherapy as Treatment for two Autoimmune Liver Diseases

2019-04-09T20:54:20+00:00April 9th, 2019|

Orbsen Therapeutics, a biotechnology company focused on the development and commercialization of first-in-class stromal cell immunotherapies, announced its second generation immunotherapy ORBCEL-C™ is being administered to patients participating in MERLIN, a multi-site United Kingdom-based clinical trial to determine the therapy’s safety and effectiveness in treating two types of chronic autoimmune liver diseases. “Orbsen’s product [...]